Latanoprost Versus Fotil

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00304785

Enrollment

Registered

2006-03-20

Start date

2005-05-31

Completion date

2007-10-31

Last updated

2007-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Open-Angle Glaucoma, Ocular Hypertension

Brief summary

To compare the intraocular pressure effect and safety of latanoprost 0.005% given every evening versus PTFC given twice daily.

Interventions

DRUGlatanoprost 0.005%

DRUGFotil

DRUGplacebo

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* adults with primary open-angle or pigment dispersion glaucoma, or ocular hypertension * untreated intraocular pressure should be between 24-36 mm Hg inclusive * visual acuity should be 5/50 or better in both eyes

Exclusion criteria

* presence of exfoliation syndrome or exfoliation glaucoma * contraindications to study medications * any anticipated change in systemic hypotensive therapy

Countries

Poland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026